Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool.
J Clin Endocrinol Metab
; 40(6): 1121-4, 1975 Jun.
Article
en En
| MEDLINE
| ID: mdl-166088
The effects of somatostatin on tolbutamide-stimulated insulin release were studied in 4 patients with insulin-producing tumors of the pancreas and in 6 normal subjects. In contrast to its effective inhibition of insulin release in normal subjects, somatostatin, without exception, failed to inhibit tolbutamide-induced insulin release in the patients with pancreatic beta-cell tumors. This differential effect of somatostatin may prove useful in the diagnosis of insulin-producing tumors of the pancreas.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Tolbutamida
/
Somatostatina
/
Adenoma de Células de los Islotes Pancreáticos
/
Insulina
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Clin Endocrinol Metab
Año:
1975
Tipo del documento:
Article